Risk Factors for Major Bleeding among Patients with Chronic Kidney Disease Treated with Acetylsalicylic Acid
Given its controversial efficacy in primary prevention of CVD in CKD patients, characterizing those at increased risk of bleeding under ASA therapy is important in the era of tailored medicine. Age, CKD stage, and cardiovascular risk are key factors to consider regarding the safety and effectiveness of ASA for CKD patients.
Authors
- Sydney Benchetrit
- Mor Saban (ORCID: https://orcid.org/0000-0001-6869-0907)
- Hadar Haim-Pinhas
- Keren Cohen‐Hagai (ORCID: https://orcid.org/0000-0003-1894-6956)
- Ilan Rozenberg
- Gil Schwartz Yoskovitz
- Ori Wand (ORCID: https://orcid.org/0000-0002-7702-2967)
- Meytal Schwartz Yoskovitz
- David Pereg (ORCID: https://orcid.org/0000-0002-3394-2032)
Institutions
- Ben-Gurion University of the Negev (IL)
- Tel Aviv University (IL)
- Meir Medical Center (IL)
- Barzilai Medical Center (IL)
Publication Details
- Journal
- Kidney & Blood Pressure Research
- Published
- 2024-11-11
- DOI
- https://doi.org/10.1159/000542500
- Citations
- 1
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.40